CLINICAL TRIAL: PACTG 1020A NOVEL PROTEASE INHIBITOR BMS-232632 IN CHILDREN WITH

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 确定BMS-232632胶囊制剂联合两种NRTI在感染艾滋病毒的儿童和青少年中的药代动力学特征和给药时间表。 确定BMS-232632与NRTIs联合用药在感染艾滋病毒的婴儿和儿童中的药代动力学特征和给药方案。 确定BMS-232632在感染艾滋病毒的婴儿、儿童和青少年中的安全性和耐受性。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Determine the pharmacokinetic profile and dosing schedule for the capsule formulation of BMS-232632 in combination with two NRTIs in HIV infected children and adolescents. Determine the pharmacokinetic profile and dosing schedule fo rhte powder formulations of BMS-232632 in combination with NRTIs in HIV infected infancts and children. Determine the safety and tolerability of BMS-232632 in HIV infected infants, children and adolescents.